VistaGen Therapeutics

VTGN

Market cap $26.2M

NEW YORK, Jan. 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 16, 2026.

SAN DIEGO, Jan. 16, 2026 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.

NEW YORK, Jan. 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”). Vistagen is a clinical-stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegati.

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) between April 1 , 202 4 and Decem ber 1 6 , 202 5, inclusive. For more information, submit a form at Vistagen Therapeutics, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.

LOS ANGELES--(BUSINESS WIRE)---- $VTGN--VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) securities between April 1, 2024 and December 16, 2025.

ATLANTA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding the risks of failure associated with Vistagen's Phase 3 PALISADE-3 trial study of fasedienol.

SAN DIEGO--(BUSINESS WIRE)---- $VTGN #Health--Robbins LLP informs investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. For more information, submit a form, email attorney Aaron Dumas.

NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, inclusive. You are hereby notified that the class action lawsuit Dan Eller v.